- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06032546
Un estudio para evaluar el cambio en la actividad de la enfermedad, los eventos adversos y cómo el fármaco se mueve por el cuerpo en participantes adultos que viven con el virus de la inmunodeficiencia humana (VIH) y que reciben una infusión intravenosa (IV) de budigalimab y/o ABBV-382
Un estudio de fase 2, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, seguridad, tolerabilidad y farmacocinética de budigalimab y/o ABBV-382 en personas que viven con el VIH que reciben terapia antirretroviral estable sometidas a interrupción analítica del tratamiento
Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic disease requiring lifelong therapy. The purpose of this study is to assess change in disease activity, adverse events, tolerability, and how the drug moves through the body.
Budigalimab and ABBV-382 are investigational drugs being developed for the treatment of HIV disease. In Part 1, participants are placed in 1 of 5 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 7 chance that participants will be assigned to placebo (A placebo is not a drug and it is not expected to have any chemical effects on your body and it is not designed to treat any disease or illness). In Part 2, eligible participants will be placed in an open-label arm to receive Budigalimab. Approximately 160 adult participants living with HIV disease on stable antiretroviral therapy (ART) willing to undergo Analytical Treatment Interruption (ATI) will be enrolled at approximately 90 sites worldwide.
In Part 1, participants will receive 4 doses of intravenous (IV) budigalimab or placebo combined with 3 doses of IV ABBV-382 or placebo for an 8 week dosing period. In Part 2, participants will receive 4 doses of open-label subcutaneous (SC) Budigalimab for a 6 week dosing period. Participants need to be stable on antiretroviral therapy to participate in the study. If participant qualifies to the study, on the day they receive the first injection, participants will be asked to stop antiretroviral medications (also referred to as analytical treatment interruption or ATI) for 112 weeks or until meeting specific criteria to restart antiretroviral medications. Participants will undergo a closely monitored ART interruption. Protocol-defined ART restart criteria includes participant's request. Participants will be followed for up to approximately 112 weeks.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. There will be an option for virtual or home health visits for some of the follow-up visits. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Berlin, Alemania, 10439
- zibp-Zentrum fuer Infektiologie /ID# 257110
-
-
Hesse
-
Frankfurt am Main, Hesse, Alemania, 60596
- Infektiologikum /ID# 257112
-
-
North Rhine-Westphalia
-
Bonn, North Rhine-Westphalia, Alemania, 53127
- Universitaetsklinikum Bonn /ID# 257113
-
-
-
-
São Paulo
-
São Paulo, São Paulo, Brasil, 04037-030
- Ricardo Diaz Scientific Solution /ID# 257335
-
-
-
-
Brussels Capital
-
Anderlecht, Brussels Capital, Bélgica, 1070
- Universite Libre de Bruxelles - Hopital Erasme /ID# 257433
-
Brussels, Brussels Capital, Bélgica, 1000
- CHU Saint Pierre /ID# 257447
-
Brussels, Brussels Capital, Bélgica, 1200
- Cliniques Universitaires UCL Saint-Luc /ID# 257444
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Bélgica, 9000
- UZ Gent /ID# 257446
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V6Z 2T1
- Spectrum Health Vancouver /ID# 260791
-
-
Ontario
-
Ottawa, Ontario, Canadá, K1H 8L6
- Ottawa Hospital Research Institute /ID# 256993
-
Toronto, Ontario, Canadá, M5G 2C4
- Duplicate_Toronto General Hospital /ID# 256994
-
-
Quebec
-
Montreal, Quebec, Canadá, H4A 3J1
- McGill University Health Centre - Glen Site. /ID# 256992
-
Québec, Quebec, Canadá, G1V 4G2
- CHU de Quebec-Université Laval hôpital CHUL /ID# 261611
-
-
Saskatchewan
-
Regina, Saskatchewan, Canadá, S4P 0W5
- Regina General Hospital - Infectious Disease Clinic /ID# 260243
-
-
-
-
-
Barcelona, España, 08036
- Hospital Clinic de Barcelona /ID# 257269
-
Madrid, España, 28034
- Hospital Universitario Ramon y Cajal /ID# 257266
-
Madrid, España, 28046
- Hospital Universitario La Paz /ID# 257170
-
-
Barcelona
-
Badalona, Barcelona, España, 08916
- Hospital Universitario Germans Trias i Pujol /ID# 257268
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35222-2309
- University of Alabama at Birmingham, 1917 Research Clinic /ID# 257549
-
-
California
-
Bakersfield, California, Estados Unidos, 93301
- Franco Felizarta, Md /Id# 256927
-
Beverly Hills, California, Estados Unidos, 90211
- AHF Research Center /ID# 257025
-
Long Beach, California, Estados Unidos, 90813-3267
- Long Beach Education and Research Consultants /ID# 257552
-
Los Angeles, California, Estados Unidos, 90027
- AHF Healthcare Center- Hollywood /ID# 257026
-
Los Angeles, California, Estados Unidos, 90028-6213
- Los Angeles LGBT Center /ID# 258407
-
Los Angeles, California, Estados Unidos, 90036
- Ruane Clinical Research Group /ID# 256932
-
Palm Springs, California, Estados Unidos, 92262
- Palmtree Clinical Research Inc. /Id# 258409
-
San Francisco, California, Estados Unidos, 94102
- Optimus Medical /ID# 257182
-
San Francisco, California, Estados Unidos, 94115-3037
- Quest Clinical Research /ID# 256928
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20017
- Washington Health Institute /ID# 259336
-
-
Florida
-
DeLand, Florida, Estados Unidos, 32720-0920
- Midland Florida Clinical Research Center /ID# 257101
-
Fort Lauderdale, Florida, Estados Unidos, 33308
- Ahf Healthcare Center - Northpoint /ID# 256934
-
Ft. Pierce, Florida, Estados Unidos, 34982
- Midway Immunology and Research Center /ID# 256930
-
Miami, Florida, Estados Unidos, 33147
- Advanced Pharma CR, LLC /ID# 259335
-
Orlando, Florida, Estados Unidos, 32803
- Orlando Immunology Center /ID# 256931
-
Orlando, Florida, Estados Unidos, 32806-3300
- Bliss Health /ID# 257827
-
Tampa, Florida, Estados Unidos, 33614
- Baycare Medical Group - Tampa /ID# 256953
-
Vero Beach, Florida, Estados Unidos, 32960-6541
- The Pierone Research Institute /ID# 257022
-
West Palm Beach, Florida, Estados Unidos, 33407
- Triple O Research Institute /ID# 256929
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30308
- Winship At Emory University Hospital Midtown /ID# 258410
-
Decatur, Georgia, Estados Unidos, 30033
- Metro Infectious Disease Consultants /ID# 256955
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60613-2010
- Howard Brown Health Center /ID# 257485
-
-
Massachusetts
-
Springfield, Massachusetts, Estados Unidos, 01105-1406
- Claudia T. Martorell MD LLC dba The Research Institute /ID# 259155
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64111
- KC CARE Health Center - Midtown South /ID# 257178
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89106
- Las Vegas Research Center /ID# 257619
-
-
New Jersey
-
Camden, New Jersey, Estados Unidos, 08103
- Cooper University Health Care - Camden /ID# 258133
-
Newark, New Jersey, Estados Unidos, 07102
- Saint Michael's Medical Center /ID# 258802
-
Somers Point, New Jersey, Estados Unidos, 08244
- South Jersey Infectious Disease /ID# 257840
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87106
- The University of New Mexico /ID# 257533
-
-
New York
-
Syracuse, New York, Estados Unidos, 13215
- Suny Upstate University Hospital Community Campus /ID# 257847
-
The Bronx, New York, Estados Unidos, 10461
- Jacobi Medical Center /ID# 257849
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center /ID# 257792
-
-
North Carolina
-
Greenville, North Carolina, Estados Unidos, 27834
- East Carolina University - Brody School of Medicine /ID# 257544
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Atrium Health Wake Forest Baptist Medical Center /ID# 257542
-
-
Texas
-
Austin, Texas, Estados Unidos, 78705-3326
- Central Texas Clinical Research /ID# 256920
-
Dallas, Texas, Estados Unidos, 75208-4599
- Prism Health North Texas - Oak Cliff Health Center /ID# 256933
-
Dallas, Texas, Estados Unidos, 75246
- North Texas Infectious Diseases Consultants, P.A /ID# 257592
-
Dallas, Texas, Estados Unidos, 75390-7208
- University of Texas Southwestern Medical Center /ID# 257551
-
Fort Worth, Texas, Estados Unidos, 76104
- Texas Center for Infectious Disease Associates /ID# 257183
-
Houston, Texas, Estados Unidos, 77098-3900
- The Crofoot Research Center, Inc /ID# 256921
-
Longview, Texas, Estados Unidos, 75605
- DCOL Center for Clinical Research /ID# 257093
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Wisconsin Medical Center /ID# 257498
-
-
-
-
-
Paris, Francia, 75012
- AP-HP - Hopital Saint-Antoine /ID# 258090
-
Paris, Francia, 75020
- AP-HP - Hopital Tenon /ID# 258091
-
-
-
-
-
Modena, Italia, 41124
- Azienda Ospedaliero-Universitaria di Modena /ID# 257411
-
-
Milano
-
Milan, Milano, Italia, 20132
- IRCCS Ospedale San Raffaele /ID# 259820
-
Milan, Milano, Italia, 20162
- ASST Grande Ospedale Metropolitano Niguarda /ID# 257410
-
-
Napoli
-
Naples, Napoli, Italia, 80131
- Azienda Ospedaliera Universitaria Federico II - Naples /ID# 257412
-
-
-
-
-
Tokyo, Japón, 108-8639
- IMSUT Hospital, The Institute of Medical Science, The University of Tokyo /ID# 265344
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japón, 460-0001
- NHO Nagoya Medical Center /ID# 261433
-
-
Osaka
-
Osaka, Osaka, Japón, 540-0006
- National Hospital Organization Osaka National Hospital /ID# 261520
-
-
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polonia, 85-030
- Wojewodzki Szpital Obserwacyjno-Zakazny im. Tadeusza Browicza /ID# 259184
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Polonia, 80-405
- Punkt Zdrowia /ID# 257950
-
-
-
-
-
San Juan, Puerto Rico, 00909-1711
- Clinical Research Puerto Rico /ID# 256956
-
San Juan, Puerto Rico, 00909
- HOPE Clinical Research /ID# 257487
-
-
-
-
Greater London
-
London, Greater London, Reino Unido, NW3 2QG
- Royal Free Hospital /ID# 257453
-
London, Greater London, Reino Unido, SE1 9RT
- Dup_Guys and St Thomas NHS Foundation Trust - Guy's Hospital /ID# 257761
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, Sudáfrica, 2001
- Wits RHI Research Centre /ID# 257354
-
Johannesburg, Gauteng, Sudáfrica, 2013
- Perinatal HIV Research Unit (PHRU) /ID# 257350
-
Johannesburg, Gauteng, Sudáfrica, 2092
- Clinical HIV Research Unit (CHRU) /ID# 257358
-
Johannesburg, Gauteng, Sudáfrica, 2193
- Ezintsha Research Centre /ID# 257391
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- A condition of general good health in the opinion of the investigator, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).
- Must be on antiretroviral therapy (ART) for at least 12 months prior to screening and on a stable ART regimen for at least 8 weeks prior to screening (current ART regimen cannot include an Non-nucleoside reverse transcriptase inhibitor [NNRTI] or long-acting ART).
- Negative human immuno-deficiency virus (HIV)-2 antibody (Ab)
- Cluster of differentiation 4 (CD4+) T cell count >= 500 cells/μL at screening and no known evidence of CD4+ T cell count < 500 cells/μL in the last 12 months prior to screening
- Participant must have plasma HIV-1 ribonucleic acid (RNA) below the lower limit of quantitation (LLOQ) at screening and for at least 12 months prior to screening
Exclusion Criteria:
- Prior exposure to long acting antiretrovirals within 24 weeks or within a period defined by 5 half-lives, whichever is longer, prior to randomization and prior to the first dose of study drug.
- History of CD4+ T cell nadir of <= 200 cells/μL during chronic HIV infection.
- History of medical disorders (other than HIV-1 infection) that, in the opinion of the investigator, might expose the participant to undue risk of harm, confound study outcomes or prevent the participant from completing the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: Arm A: Placebo
Participants will receive budigalimab placebo on Day 1, and Weeks 2, 4, and 6 in combination with ABBV-382 matching placebo on Day 1 and Weeks 4 and 8. |
IV Infusion IV Infusion |
|
Experimental: Arm B: Budigalimab Dose A
Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 matching placebo Day 1 and Weeks 4 and 8. |
IV Infusion Intravenous (IV) Infusion
Otros nombres:
Subcutaneous (SC) Injection
Otros nombres:
|
|
Experimental: Arm C: ABBV-382 Dose A
Participants will receive budigalimab placebo on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose A on Day 1 and Weeks 4 and 8. |
IV Infusion IV Infusion |
|
Experimental: Arm D: Budigalimab Dose A + ABBV-382 Dose B
Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose B on Day 1 and Weeks 4 and 8. |
Intravenous (IV) Infusion
Otros nombres:
Subcutaneous (SC) Injection
Otros nombres:
IV Infusion |
|
Experimental: Arm E: Budigalimab Dose A + ABBV-382 Dose A
Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose A on Day 1 and Weeks 4 and 8. |
Intravenous (IV) Infusion
Otros nombres:
Subcutaneous (SC) Injection
Otros nombres:
IV Infusion |
|
Experimental: Arm F: Budigalimab Dose B
Participants will receive open-label budigalimab Dose B on Day 1 and Weeks 2, 4, and 6 (Note, no ABBV-382 or placebo will be administered). |
Intravenous (IV) Infusion
Otros nombres:
Subcutaneous (SC) Injection
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of Participants With Viral Control Without Antiretroviral Therapy (ART) Restart
Periodo de tiempo: Week 24
|
Percentage of participants who achieve viral control (viral load < 1000 copies/mL) without ART restart at Week 24. |
Week 24
|
|
Number of Participants With Adverse Events (AEs)
Periodo de tiempo: Up to approximately Week 112
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Up to approximately Week 112
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Median Peak Log10 Viral Load (At Rebound) Prior to Re-Starting ART
Periodo de tiempo: Up to 112 weeks
|
The median peak log10 viral load (at rebound) before re-starting ART. |
Up to 112 weeks
|
|
Median Time to First Rebound to ≥ 1000 Copies/mL During ART Interruption
Periodo de tiempo: Up to 112 weeks
|
The median time to first rebound to ≥ 1000 copies/mL during ART interruption. |
Up to 112 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: ABBVIE INC., AbbVie
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- M19-965
- 2023-505900-53-00 (Otro identificador: EU CT)
- 2023 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Marco de tiempo para compartir IPD
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Criterios de acceso compartido de IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .